Arcutis Biotherapeutics (ARQT) announced the commercial launch of ZORYVE cream 0.05% for the treatment of mild to moderate atopic dermatitis in children ages 2 to 5 years in the United States. ZORYVE cream 0.05% will be available in pharmacies this week. The product is being reviewed by commercial pharmacy benefit managers and other plans to enable similar coverage as the entire ZORYVE portfolio.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARQT:
- Arcutis Biotherapeutics price target raised to $29 from $19 at Goldman Sachs
- Arcutis Biotherapeutics price target raised to $32 from $26 at Mizuho
- Arcutis Biotherapeutics price target raised to $30 from $22 at H.C. Wainwright
- Arcutis Biotherapeutics Reports Strong Q3 Earnings Call
- Arcutis Biotherapeutics: Strong Sales and Growth Prospects Justify Buy Rating